|
nasdaq:sgen
|
https://www.indeed.com/cmp/seattle-genetics
|
Aug 29th, 2022 12:00AM
|
Open
|
Seagen
|
|
Pharmaceutical & Biotechnology
|
Targeting Cancer. Transforming Therapies.
Revolutionary science meets transformative cancer therapy
Seagen is dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells.
The largest global oncology biotechnology company based in the Pacific Northwest, we are focused on developing and commercializing a new generation of targeted, empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer.
Our industry-leading antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary technology, we are able to optimize each ADC to potentially improve outcomes for patients. ADCs are an integral part of the evolving cancer treatment paradigm with their specificity, stability and potency.
|
RRv1_100M_500M
|
Bothell, WA
|
Clay Siegall, Ph.D.
|
|
|
3.50
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
39.00
|
39.00
|
3.30
|
3.60
|
2.90
|
2.80
|
3.40
|
17.00
|
About two weeks
|
18.00
|
MEDIUM
|
17.00
|
FAVORABLE
|
|
|
|
Aug 29th, 2022 12:34PM
|
Aug 29th, 2022 12:34PM
|
Seattle Genetics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:sgen
|
https://www.indeed.com/cmp/oncothyreon
|
Aug 29th, 2022 12:00AM
|
Open
|
Oncothyreon
|
|
|
|
|
|
|
|
|
3.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aug 29th, 2022 12:34PM
|
Aug 29th, 2022 12:34PM
|
Seattle Genetics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:sgen
|
https://www.indeed.com/cmp/seattle-genetics
|
Aug 28th, 2022 12:00AM
|
Open
|
Seagen
|
|
Pharmaceutical & Biotechnology
|
Targeting Cancer. Transforming Therapies.
Revolutionary science meets transformative cancer therapy
Seagen is dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells.
The largest global oncology biotechnology company based in the Pacific Northwest, we are focused on developing and commercializing a new generation of targeted, empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer.
Our industry-leading antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary technology, we are able to optimize each ADC to potentially improve outcomes for patients. ADCs are an integral part of the evolving cancer treatment paradigm with their specificity, stability and potency.
|
RRv1_100M_500M
|
Bothell, WA
|
Clay Siegall, Ph.D.
|
|
|
3.50
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
39.00
|
39.00
|
3.30
|
3.60
|
2.90
|
2.80
|
3.40
|
17.00
|
About two weeks
|
18.00
|
MEDIUM
|
17.00
|
FAVORABLE
|
|
|
|
Aug 28th, 2022 05:34AM
|
Aug 28th, 2022 05:34AM
|
Seattle Genetics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:sgen
|
https://www.indeed.com/cmp/oncothyreon
|
Aug 28th, 2022 12:00AM
|
Open
|
Oncothyreon
|
|
|
|
|
|
|
|
|
3.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aug 28th, 2022 05:34AM
|
Aug 28th, 2022 05:34AM
|
Seattle Genetics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:sgen
|
https://www.indeed.com/cmp/seattle-genetics
|
Aug 27th, 2022 12:00AM
|
Open
|
Seagen
|
|
Pharmaceutical & Biotechnology
|
Targeting Cancer. Transforming Therapies.
Revolutionary science meets transformative cancer therapy
Seagen is dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells.
The largest global oncology biotechnology company based in the Pacific Northwest, we are focused on developing and commercializing a new generation of targeted, empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer.
Our industry-leading antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary technology, we are able to optimize each ADC to potentially improve outcomes for patients. ADCs are an integral part of the evolving cancer treatment paradigm with their specificity, stability and potency.
|
RRv1_100M_500M
|
Bothell, WA
|
Clay Siegall, Ph.D.
|
|
|
3.50
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
39.00
|
39.00
|
3.30
|
3.60
|
2.90
|
2.80
|
3.40
|
17.00
|
About two weeks
|
18.00
|
MEDIUM
|
17.00
|
FAVORABLE
|
|
|
|
Aug 27th, 2022 04:52AM
|
Aug 27th, 2022 04:52AM
|
Seattle Genetics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:sgen
|
https://www.indeed.com/cmp/oncothyreon
|
Aug 27th, 2022 12:00AM
|
Open
|
Oncothyreon
|
|
|
|
|
|
|
|
|
3.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aug 27th, 2022 04:52AM
|
Aug 27th, 2022 04:52AM
|
Seattle Genetics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:sgen
|
https://www.indeed.com/cmp/oncothyreon
|
Aug 25th, 2022 12:00AM
|
Open
|
Oncothyreon
|
|
|
|
|
|
|
|
|
3.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aug 25th, 2022 09:32AM
|
Aug 25th, 2022 09:32AM
|
Seattle Genetics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:sgen
|
https://www.indeed.com/cmp/seattle-genetics
|
Aug 25th, 2022 12:00AM
|
Open
|
Seagen
|
|
Pharmaceutical & Biotechnology
|
Targeting Cancer. Transforming Therapies.
Revolutionary science meets transformative cancer therapy
Seagen is dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells.
The largest global oncology biotechnology company based in the Pacific Northwest, we are focused on developing and commercializing a new generation of targeted, empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer.
Our industry-leading antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary technology, we are able to optimize each ADC to potentially improve outcomes for patients. ADCs are an integral part of the evolving cancer treatment paradigm with their specificity, stability and potency.
|
RRv1_100M_500M
|
Bothell, WA
|
Clay Siegall, Ph.D.
|
|
|
3.50
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
39.00
|
39.00
|
3.30
|
3.60
|
2.90
|
2.80
|
3.40
|
17.00
|
About two weeks
|
18.00
|
MEDIUM
|
17.00
|
FAVORABLE
|
|
|
|
Aug 25th, 2022 09:32AM
|
Aug 25th, 2022 09:32AM
|
Seattle Genetics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:sgen
|
https://www.indeed.com/cmp/seattle-genetics
|
Aug 23rd, 2022 12:00AM
|
Open
|
Seagen
|
|
Pharmaceutical & Biotechnology
|
Targeting Cancer. Transforming Therapies.
Revolutionary science meets transformative cancer therapy
Seagen is dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells.
The largest global oncology biotechnology company based in the Pacific Northwest, we are focused on developing and commercializing a new generation of targeted, empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer.
Our industry-leading antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary technology, we are able to optimize each ADC to potentially improve outcomes for patients. ADCs are an integral part of the evolving cancer treatment paradigm with their specificity, stability and potency.
|
RRv1_100M_500M
|
Bothell, WA
|
Clay Siegall, Ph.D.
|
|
|
3.50
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
39.00
|
39.00
|
3.30
|
3.60
|
2.90
|
2.80
|
3.40
|
17.00
|
About two weeks
|
18.00
|
MEDIUM
|
17.00
|
FAVORABLE
|
|
|
|
Aug 23rd, 2022 11:25AM
|
Aug 23rd, 2022 11:25AM
|
Seattle Genetics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:sgen
|
https://www.indeed.com/cmp/oncothyreon
|
Aug 23rd, 2022 12:00AM
|
Open
|
Oncothyreon
|
|
|
|
|
|
|
|
|
3.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aug 23rd, 2022 11:25AM
|
Aug 23rd, 2022 11:25AM
|
Seattle Genetics
|
Health Care
|
Pharmaceuticals & Biotechnology
|